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Introduction: The objective of this study was to assess the ability to test patients for carbon 
monoxide (CO) exposure in all hospitals in three United States (U.S.) Midwestern states.
Methods: We surveyed hospitals in three states. Telephone queries assessed processes for 
measuring carboxyhemoglobin, including capacity for real-time vs send-out testing. Facilities were 
separated based on their location’s population size for further analysis. Descriptive statistics are 
reported.
Results: Of the 250 hospitals queried, we ultimately excluded 25. Nearly all (220, 97.8%) reported 
a process in place to test for CO exposure. Over 40% (n=92) lacked real-time testing. Testing ability 
was positively associated with increasing population size quartile (range 32.6% - 100%). Hospitals in 
the lowest-quartile population centers were more likely to report that they were unable to test in real 
time than those in the largest-quartile population centers (67.4% vs 0%). 
Conclusion: In a large geographic region encompassing three states, hospital-based and real-time 
capacity to test for CO exposure is not universal. Hospitals in smaller population areas are more 
likely to lack real-time testing or any testing at all. This may have significant public health, triage, and 
referral implications for patients. [West J Emerg Med. 2019;20(3)506–511.]
INTRODUCTION
Carbon monoxide (CO) is an odorless and invisible 
gas that may not be apparent to individuals exposed to 
it. Yet as a byproduct of combustion from sources such as 
furnaces, heaters, and engines, CO is pervasive in modern 
life. CO poisoning occurs when an individual is exposed to 
the gas at sufficient concentrations to cause symptoms with 
or without end-organ dysfunction. It is one of the leading 
causes of poisoning in the United States (U.S.) and around 
the world.1 It has been estimated that CO poisoning is 
Hennepin Healthcare, Department of Emergency Medicine, Minneapolis, Minnesota 
responsible for 50,000 emergency department (ED) visits in 
the U.S. annually.2 Public health and legislative efforts have 
sought to increase awareness of CO poisoning and the use 
of CO detectors. This has contributed to fewer ED visits and 
deaths, particularly among intentional exposures. However, 
accidental exposures have diminished at a slower pace, 
and the rate of hospitalizations for CO poisoning remains 
essentially unchanged.3-6 
Legislation requiring CO detectors in certain 
settings has helped to make significant environmental 
Volume 20, no. 3: May 2019 507 Western Journal of Emergency Medicine
Masters et al. Availability of Bedside and Laboratory Testing for CO Poisoning
Population Health Research Capsule
What do we already know about this issue?
Carbon monoxide poisoning is one of the 
leading causes of poisoning in the United States.
What was the research question?
How available are methods for detecting 
carbon monoxide (CO) poisoning in hospitals 
in the upper Midwest?
What was the major finding of the study?
Hospitals serving smaller population areas 
are more likely to lack real-time testing for 
CO exposures.
How does this improve population health?
Understanding resource gaps could spur 
increased availability of point of care testing 
in smaller communities. 
exposures less frequent and, when present, more 
apparent to clinicians.7,8 In the absence of scene alarms 
or source exposure history, the vague and nonspecific 
nature of presenting symptoms can make diagnosis a 
challenge. Patients may present with symptoms ranging 
from headache and dizziness, nausea and vomiting, to 
coma.9 While history and physical findings may point 
to the diagnosis, clinicians must maintain a high degree 
of suspicion. A missed diagnosis can have significant 
consequences, as CO poisoning can cause acute and 
persistent neurologic and cardiac injury,10 and therapy, 
whether with normobaric or hyperbaric oxygen, must 
be initiated in a timely manner.11 It is recommended that 
the diagnosis of CO poisoning should be confirmed by 
detecting an elevated carboxyhemoglobin (HbCO) level in 
the context of clinical symptoms.12,13 In the absence of real-
time testing, therapy, hospitalization and referrals may be 
necessary based on clinical suspicion alone.
In the U.S., two common methods to detect HbCO in 
poisoned patients are a venous blood assay and finger CO-
oximetry. A blood assay is the oldest method, but requires a 
laboratory equipped to perform the test.14,15 While the blood 
assay is the gold standard, non-invasive finger CO-oximetry 
has been touted as a potential cost-effective surrogate for 
screening.16-18 However, it is unclear how available either 
of these methods are to practicing clinicians. The goal of 
this study was to evaluate hospital capabilities of detecting 
carbon CO poisoning in three states in the upper Midwest. 
METHODS
We conducted a cross-sectional study of hospitals 
distributed over three Midwestern U.S. states (Minnesota, 
North Dakota, and South Dakota) served by both a single 
regional poison center – the Minnesota Poison Control System 
– and a single center for hyperbaric medicine with emergent 
treatment capabilities – the Hennepin County Medical Center 
Department of Undersea and Hyperbaric Medicine. We used 
multiple available sources, including state trauma databases, 
state health department websites, and the regional poison-
center’s hospital database, to identify and compile all of 
the hospitals within the three-state area. All the identified 
hospitals were contacted by phone and surveyed from August 
1, 2017 – May 3, 2018. Facilities were excluded if they did 
not have an emergency department (ED) (such as freestanding 
clinics) or if the hospital was no longer open. 
We surveyed each facility in a standardized format 
regarding its ability to test for CO poisoning. Specific 
inquiries included whether the facility possessed in-house 
spectrophotometric HbCO assays, bedside CO-oximetry, or 
any manner to test for CO exposure on site. Additionally, 
facilities were queried regarding their use of send-out testing 
for CO exposure, as well as whether a process was in place to 
facilitate real-time testing. 
We directed initial inquiries to the hospital-
based clinical laboratory. A standardized greeting and 
introduction was followed by a simple query regarding 
capability to assay HbCO in the hospital lab, and a 
subsequent query with respect to the availability of bedside 
CO-oximetry at the facility. If the study inquiries were 
unanswered by laboratory staff or laboratory supervisor, a 
follow-up call to the ED was made. Following standardized 
introduction, a query was repeated with respect to the 
availability of bedside CO-oximetry to the supervising 
nurse on duty. 
The reported populations of towns and cities housing 
each hospital were abstracted from the most recent United 
States Census Bureau dataset (USCB, 2010). These 
populations were divided into settlement hierarchy19 
quartiles of ≤2,500, 2,501 - 25,000, 25,001 - 250,000, and 
≥250,000 inhabitants with the assumption that hospitals 
in larger communities would be more likely to have a full 
range of care resources.  Hospitals were further described 
with respect to their American College of Surgeons (ACS) 
trauma designation as an additional possible marker of 
available resources. For example, Level IV trauma center 
certification by the ACS requires 24-hour laboratory 
coverage, while Level V certification does not.20 
Descriptive statistics characterizing study data were 
calculated in Stata/IC 15.0 for Mac (College Station, Texas). 
Relationships between the binary availability of HbCO 
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testing and independent variables, including locale size, and 
American Trauma Society (ATS) trauma designation are 
reported using x2 or Fisher’s exact tests, as appropriate.
RESULTS
We identified 250 facilities within the catchment area 
of the regional poison center and hyperbaric medicine unit. 
Included in the final analysis were 225 facilities (Table 1). 
Of the 25 facilities excluded, none were excluded due to 
failed contact, but three were excluded because the facility 
was no longer operational. Thirteen were specialty centers 
without a functioning ED, and nine were clinics or long-
term care facilities (Figure 1). The population of the cities 
in which all hospitals were located, based on 2010 USCB 
results, ranged from 446 to 382,578 people.
Most facilities (181, 80.4%) were located in areas 
populated by less than 25,000 people. Hospital density 
per population was not equally distributed across the three 
states, with one for every 42,094 in Minnesota, one facility 
for every 15,286 inhabitants in North Dakota, and one for 
every 14,803 in South Dakota (Figure 2). Similarly, higher 
ATS trauma classification hospitals were more common to 
Minnesota than North Dakota or South Dakota.
Nearly all hospitals (n=220, 97.8%) reported some 
means of testing for CO poisoning (Table 2). A majority 
of facilities (n=133, 59.11%) reported some capacity for 
real-time testing. Facilities with more advanced trauma 
designations typically had greater ability to evaluate HbCO 
levels (Table 2). The proportion of hospitals capable of real-
time HbCO measurement increased with population size 
from the lowest quartile at 32.6% to the highest quartile 
at 100% (Fisher’s exact test = 0.000). Smaller population 
size was associated with a higher proportion of hospitals 
reporting the use of send-out HbCO assays (Fisher’s exact 
test = 0.000). We also identified a strong association between 
reporting a lack of real-time testing and the use of send-
out labs (Pearson’s x2 = 90, p = 0.000), an association that 
persisted across all hospital population strata. 
City size All states Minnesota North Dakota South Dakota
Total n (%)* 225 126 44 55
<2,500 89 (39.6) 31 (24.6) 29 (65.9) 29 (52.7)
2,501 – 25,000 92 (40.9) 67 (53.2) 7 (15.9) 18 (32.7)
25,001 – 250,000 34 (15.1) 18 (14.3) 8 (18.2) 8 (14.6)
>250,000 10 (4.44) 10 (7.94) 0 (0.00) 0 (0.00)
Table 1. Distribution of responding hospitals.
* Percentage of responding hospitals located in cities of a given size.
250 Hospitals identified
25 Excluded
0 Failed contact
13 Specialty hospital, surgicenter, 
or no emergency department
9 Clinic / long-term care facility
3 No longer open
126 Minnesota
< 2,500:  31
2,501 - 25,000:  67
25,001 - 250,000:  18
> 250,000:  10
44 North Dakota
< 2,500:  29
2,501 - 25,000:  7
25,001 - 250,000:  8 
> 250,000:  0
55 South Dakota
< 2,500:  29
2,501 - 25,000:  18
25,001 - 250,000:  8
> 250,000:  0
Figure 1. Study flow diagram of hospital capability to test for carbon monoxide poisoning.
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25,001 - 250,000
2,501 - 25,000
>250,000
<2,500
Real-time carboxyhemoglobin assessment (laboratory or CO-oximetry)
Figure 2. Distribution of responding hospitals and real-time carboxyhemoglobin monitoring by community size.
CO, carbon monoxide.
COHb lab assay Finger CO-oximetry Real-time COHb Unable to test
Total n (%) 91 (29.6) 78 (25.4) 133 (43.3) 5 (1.62)
Population size
<2,500 9 (10.1) 23 (25.8) 29 (32.6) 5 (5.62)
2,501 – 25,000 48 (52.2) 38 (41.3) 65 (70.7) 0 (0.00)
25,001 – 250,000 24 (70.6) 15 (44.1) 29 (85.3) 0 (0.00)
>250,000 10 (100.0) 2 (20.0) 10 (100.0) 0 (0.00)
ACS trauma designation
I 5 (100.0) 4 (80.0) 5 (100.0) 0 (0.00)
II 12 (80.0) 5 (33.3) 15 (100.0) 0 (0.00)
III 25 (89.3) 12 (42.9) 27 (96.4) 0 (0.00)
IV 40 (35.4) 43 (38.1) 67 (59.3) 1 (0.88)
V 3 (7.0) 7 (16.3) 8 (18.6) 4 (9.30)
n/a 6 (28.6) 7 (33.3) 11 (54.2) 0 (0.00)
COHb, carboxyhemoglobin; CO, carbon monoxide; ACS, American College of Surgeons.
Table 2. Availability of carboxyhemoglobin assessment.
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DISCUSSION
In this study of all hospitals in a three-state area, we found 
that most hospitals have some capacity for real-time testing of 
patients’ HbCO levels. However, smaller population areas were 
associated with gaps in real-time testing for HbCO and the use 
of send-out assays. Although it has been widely suspected that 
CO poisoning is underdiagnosed and under-reported in general, 
to our knowledge there have been no other studies looking at 
regional capabilities of detecting CO exposure and associated 
poisoning in the past decade, with only one similar study done 
in a different region of the U.S. in 2003 – 2004.21 
A Centers for Disease Control and Prevention editorial 
noted concerns that CO poisoning may also be under-
reported to poison centers in particular.22 Our data suggest 
that most hospitals in areas of less than 2500 people lack 
the ability to do real-time testing for CO exposure. Given 
that send-out assays often involve significant turnaround 
time and resources,23 it is possible that under-reporting and 
underdiagnosis of associated CO poisonings may be related to 
gaps in the capacity to detect HbCO levels. 
The invisible nature of the gas and the vague presenting 
symptoms can make CO poisoning difficult to suspect and 
diagnose clinically, requiring a high degree of suspicion.9 
Without a readily available means of testing, clinicians are 
unable to confirm the diagnosis. It is conceivable then that gaps 
in the regular availability of confirmatory testing might lead to 
cognitive biases24 that would prevent clinicians from suspecting 
or settling upon the diagnosis of CO poisoning in atypical 
presentations. Without suspicion or diagnosis, patients cannot 
be appropriately triaged or treated in a timely manner, whether 
with normobaric oxygen, hyperbaric oxygen, or other therapies. 
This study did not look into hospital referral patterns; however, 
previous studies have shown that 90% of patients referred for 
hyperbaric oxygen therapy come from facilities capable of 
testing in real time.21 Although referrals may be based on clinical 
suspicion, we suspect that this presents a clinical conundrum for 
both the referring clinician and the accepting facility.  
Many of the facilities that we surveyed were in rural 
areas. Although facilities located in larger urban or suburban 
areas tended to possess better testing capabilities, rates of CO 
poisoning have been shown to be higher in rural areas.4 Work-
related exposures and faulty furnaces account for significant 
sources of CO poisonings (45% in one study).25 Indeed, given 
current rural infrastructure and livelihoods, our concern is that 
individuals using gas heating implements or working on heavy 
and possibly running machinery in poorly-ventilated areas 
such as barns and sheds are more likely to be exposed, to go 
undiagnosed or be misdiagnosed, and to then return to the same 
practices that led to the exposure, compounding morbidity and 
increasing the likelihood of mortality from CO poisoning.
Historically, the majority of CO exposures in the U.S. 
have occurred in the Midwest, particularly accidental 
exposures.22 Indeed, sparse populations and rural areas with less 
infrastructure, particularly in North Dakota and South Dakota, 
do make these states distinct from much of the country. This area 
of the country also experiences significant cold-weather seasons, 
leading people to spend significant periods of time indoors with 
heaters, furnaces, and other sources of combustion, and it is 
during these colder months that the greatest number of poisonings 
occur.4-6 It is therefore of significant concern that many facilities 
in this upper Midwestern region do not have real-time capacity 
for detection of CO.  
We believe that every hospital should possess some 
manner of real-time testing for CO poisoning. Delayed or 
missed diagnosis can have real effects on clinical outcomes.11 
In addition, although prevention is key, all exposed patients 
should be afforded an opportunity to be appropriately 
evaluated for and diagnosed with CO poisoning so that they 
receive timely, appropriate treatment.
LIMITATIONS
There are several limitations to this study. First, it is 
possible that we did not survey every hospital in the three 
states of concern. However, given our efforts to cross-reference 
multiple sources, we feel that this is a representative and nearly 
comprehensive sampling of hospitals in this geographic area. 
Second, it is possible that the individuals describing testing 
capabilities were inaccurate in their characterizations. However, 
we feel that the senior staff surveyed are likely to reflect a 
reasonable knowledge of the facility’s capabilities. Third, we 
did not quantify the turnaround time for send-out labs at each 
facility. Given that many of these hospitals are in remote areas, 
it is reasonable to assume that it would be at the very least 
several hours for results to return, especially when snowstorms 
and other weather events impact the region. 
Additionally, we did not inquire about prehospital 
or out-of-hospital detection capacity or other established 
processes that might facilitate the diagnosis and treatment of 
CO poisoning, nor did we inquire about specific algorithms 
regarding the management of suspected CO poisoning, both of 
which are beyond the scope of this study. Finally, it is difficult 
to know if we can extrapolate the data from these three upper 
Midwestern states to the rest of the U.S.  However, our data 
do compare favorably with a previous study.21 Additionally, if 
these gaps in testing capacity are present in areas with a high 
incidence of CO poisoning, they might well be suspected in 
areas of lower incidence across the country.
CONCLUSION
In the geographic region encompassing Minnesota, 
North Dakota, and South Dakota, hospital-based and real-
time capacity to test for CO exposure is not universal. In 
smaller population areas, hospitals are more likely to lack 
real-time testing or any testing at all. These findings may have 
significant public health, triage, and referral implications for 
patients who may be victims of CO exposure.
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